个性化文献订阅>期刊> European Journal of Medicinal Chemistry
 

Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl) cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor

  作者 Al Hussainy, R; Verbeek, J; van der Born, D; Booij, J; Herscheid, JDM  
  选自 期刊  European Journal of Medicinal Chemistry;  卷期  2011年46-12;  页码  5728-5735  
  关联知识点  
 

[摘要]Fluorinated analogs that are related to the 5-hydroxytryptamine (5-HT(1A)) antagonist, N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635), have been synthesized and their binding affinity for the 5-HT(1A) receptor and other neurotransmitter receptors (adrenoceptors, sigma receptors, and dopamine receptors), and serotonin transporters was examined in vitro. These ligands were designed to provide a possible potential positron emission tomography (PET) ligand with high metabolic stability. To this end, the cyclohexyl moiety in WAY-100635 and in O-desmethyl WAY-100635 was replaced by a bridge-fused ring (BFR) such as adamantyl, cubyl, bicyclo[2.2.2] octyl and bicyclo[2.2.1]heptyl to reduce the metabolic rate of the amide bond hydrolysis, while a fluoromethyl group was introduced on the other bridgehead of the BFR to prevent defluorination by HE elimination. All synthesized analogs displayed high affinity in the (sub)nanomolar range for the 5-HT(1A) receptor, comparable to WAY-100635. In addition, 6b, 6c and 6d were reasonably selective to the 5-HT(1A) receptor over the above mentioned receptors. In human hepatocytes, 6b showed a suitable metabolic stability.In conclusion, the obtained data provides a promising starting point for the synthesis of the corresponding (18)F-labeled PET analogs. (C) 2011 Elsevier Masson SAS. All rights reserved.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内